Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scancell updates on cancer vaccine Phase I clinical trial
Scancell is developing SCIB1 for the treatment of cancer and infectious diseases based on its ImmunoBody technology platform. The trial, which was started in June 2010, is intended
Scancell is developing SCIB1 for the treatment of cancer and infectious diseases based on its ImmunoBody technology platform. The trial, which was started in June 2010, is intended
In the study Zohydro showed improved chronic pain relief in comparison to placebo. Additionally, the study also met the two secondary endpoints, specifically, the proportion of patients with
The plant offers capacity and capability for the manufacture of several solid dosage forms. In addition to standard manufacturing capabilities, the facility offers advanced tablet production: bi-layer, tri-layer,
With this, the original deal signed in December 2005 has been extended thrice and it now covers a range of drug discovery programs. The programs use Argenta’s expertise
Endo Pharma has originally signed the deal in February 2009, under which Grunenthal has given axomadol development and marketing rights Endo in the US and Canada. The results
Developed under the collaboration with Abbott, TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical protein therapeutic in development as a treatment for B-cell malignancies. The company expects to recruit
The development was done to avoid problems caused by increasing data volumes and this system will be made available across Bio-Rad’s European sites in Germany, Italy and the
The resubmission was done following the issuing of complete response letter (CRL) by the FDA in February 2011. Taliglucerase alfa is Pfizer‘s proprietary plant cell expressed recombinant form
Crizotinib is indicated as a treatment for patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC). Bosutinib is indicated as a treatment for patients with newly
Australia’s Department of Health and Ageing is investing $466.7m over two years to build the PCEHR system which aids patients to control what is stored in health records,